

AME Case Series Checklist –Adapted from CARE Checklist and PROCESS Checklist

Section	Item	Checklist description	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title	1	The diagnosis or intervention of primary focus followed by the words “case series”.	page1/line2-3	title
Key Words	2	2 to 5 key words that identify diagnoses or interventions in this case series, including "case report" or "case series".	page2/line54-55	Keywords
Abstract (no references)	3a	Introduction—What is unique about this case series and what does it add to the scientific literature?	page1/line28-30	abstract/Paragraph 1
	3b	Methods—describe what was done, how and when was it done and by whom.	page1/line31-33	abstract/Paragraph 2
	3c	Results—what was found.	page2/line34-42	abstract/Paragraph 3
	3d	Conclusion—What is the main take-away lesson(s)? What have we learned and what does it mean?	page2/line43-48	abstract/Paragraph 4
Introduction	4	Explain the scientific background and rationale for the case series. What is the unifying theme - common disease, exposure, intervention and outcome, etc. Why is this study needed?	page2-3/line56-99	Introduction/Paragraph1-5
Methods	5a	Registration and ethics— 5a.1 State the research registry number in accordance with the declaration of Helsinki - “Every research study involving human subjects must be registered in a publicly accessible database” (this can be obtained from; ResearchRegistry.com or ClinicalTrials.gov or ISRCTN). 5a.2 State whether ethical approval was passed. 5a.3 Provide the patient consent form too.	page16/line517-523	Ethical Statement/Paragraph 4
	5b	Study design—state the study is a case series and whether prospective or retrospective in design, whether single or multi-center and whether cases are consecutive or non-consecutive.	page4/line102-114	Methods/Paragraph 1-2
	5c	Setting - describe the setting(s)and nature of the institution in which the patient was managed; academic, community or private practice setting? Location(s), and relevant dates, including periods of recruitment, exposure, follow-up, and data collection.	page4/line115-124	Methods/Paragraph 3
	5d	Participants— 5d.1 Describe the relevant characteristics of the participants (history, comorbidities, tumor staging, smoking, etc.). 5d.2 State any eligibility (inclusion/exclusion) criteria and the sources and methods of selection of participants.	page4/line115-124	Methods/Paragraph 3

	5e	Intervention—types of intervention (such as pharmacologic, surgical, preventive, self-care) deployed and reasoning behind treatment offered. Pharmacological therapies should include formulation, dosage, strength, route and duration.	page4/line126-136	Methods/Paragraph 4
	5f	Follow up—describe length and methods of follow-up.	None	None
Results	6a	Participants—reports numbers involved and their characteristics (comorbidities, tumor staging, smoking, etc.).	page5-7/line 145-219	Results/Paragraph 1-4
	6b	Any changes in the interventions during the course of the case series (how has it evolved, been tinkered with, what learning occurred, etc.) together with rationale and a diagram if appropriate.	page5-7/line145-219	Results//Paragraph 1-4
	6c	Outcomes and follow-up—Clinician assessed and patient-reported outcomes (when appropriate) should be stated with inclusion of the time periods at which assessed. Relevant photographs/radiological images should be provided. e.g. 12-month follow-up.	page5-7/line 145-219	Results/Paragraph 1-4
	6d	Where relevant—intervention adherence/compliance and tolerability (how was this assessed). Describe loss to follow-up (express as a percentage) and any explanations for it.	page7-13/line 221-420	Results/Paragraph 5-22
	6e	Complications and adverse or unanticipated events.	page5-7/line 145-219	Results/Paragraph 1-4
Discussion	7a	Summarize key results.	page14-15/line466-478	Discussion/Paragraph 4
	7b	Discussion of the relevant literature, implications for clinical practice guidelines. How do outcomes compare with established therapies and the prevailing gold standard? Generate a hypothesis if possible.	page14/line449-465	Discussion/Paragraph 3
	7c	Strengths and limitations of the study.	page15/line479-490	Discussion/Paragraph 5
	7d	The rationale for any conclusions.	page15/line491-501	Discussion/Paragraph 6
Conclusion	8a	State the key conclusions from the study.	page15/line479-490	Discussion/Paragraph 5
	8b	State what needs to be done next, further research with what study design.	page15/line491-501	Discussion/Paragraph 6

Article information: <https://dx.doi.org/10.21037/gs-21-853>

*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.